Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Director David S. Tierney Sells 15,000 Shares

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Director David S. Tierney sold 15,000 shares of the stock in a transaction dated Wednesday, August 21st. The shares were sold at an average price of $20.10, for a total transaction of $301,500.00. Following the completion of the transaction, the director now owns 348,874 shares of the company’s stock, valued at approximately $7,012,367.40. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Catalyst Pharmaceuticals Price Performance

Shares of NASDAQ CPRX opened at $20.32 on Friday. Catalyst Pharmaceuticals, Inc. has a 12-month low of $11.55 and a 12-month high of $20.87. The company has a market capitalization of $2.40 billion, a PE ratio of 37.63 and a beta of 0.70. The firm’s 50-day moving average is $17.00 and its two-hundred day moving average is $15.99.

Analysts Set New Price Targets

A number of analysts recently commented on CPRX shares. Oppenheimer reissued an “outperform” rating and set a $29.00 price objective on shares of Catalyst Pharmaceuticals in a report on Thursday, June 6th. Citigroup boosted their price objective on shares of Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a “buy” rating in a report on Friday, August 9th. StockNews.com raised shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, August 9th. HC Wainwright boosted their price objective on shares of Catalyst Pharmaceuticals from $26.00 to $30.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Finally, Truist Financial boosted their price objective on shares of Catalyst Pharmaceuticals from $25.00 to $30.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $29.50.

Institutional Trading of Catalyst Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of CPRX. Parkside Financial Bank & Trust acquired a new position in shares of Catalyst Pharmaceuticals in the fourth quarter valued at approximately $31,000. GAMMA Investing LLC raised its position in shares of Catalyst Pharmaceuticals by 72.9% in the first quarter. GAMMA Investing LLC now owns 1,942 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 819 shares during the last quarter. CWM LLC raised its position in shares of Catalyst Pharmaceuticals by 686.5% in the second quarter. CWM LLC now owns 4,066 shares of the biopharmaceutical company’s stock valued at $63,000 after buying an additional 3,549 shares during the last quarter. Meeder Asset Management Inc. acquired a new position in shares of Catalyst Pharmaceuticals in the second quarter valued at approximately $70,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Catalyst Pharmaceuticals in the second quarter valued at approximately $153,000. Hedge funds and other institutional investors own 79.22% of the company’s stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.